Paradigm Trial

Question 1

Into Facts

Answer 1

• largest Hf trial conducted.
• studied 8,442 adult patients with sympotmatic HF. specifically patients who were NYHA class 2-4.
• outpatient setting

Question 2

Objective of Trial

Answer 2

the trial compared sacubitril valsartan and enalapril. It’s objective was to prove that Entresto could reduce the risk of cardiovascular death and hospitializations for HF over enalapril

Question 3

5 most common adverse reactions

Answer 3

• hypotension 18%vs 12% (more with entresto)
• hyperkalemia 12% vs 14% (less w/entresto)
• cough 9% vs 13% (less w/entresto)
• dizziness 6% vs 5% (more w/entresto)
• renal failure (outcomes were the same with both)

Question 4

Benefits of Paradigm

Answer 4

• enalapril was the standard of care for years for patients with HF
• trial proved Entresto was superior to enalapril for reducing HF hospitalizations & death.
• patients w/HFrEF can be more confident that there is a medication out there they can rely on to give them a better quality of life.